• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性胆汁性胆管炎对熊去氧胆酸治疗生化反应的影响因素及预测评分模型

Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment.

作者信息

Chen Jialiang, Xue Dongying, Gao Fangyuan, Tao Le, Li Yuxin, Zhang Qun, Wang Rui, Sun Le, Yang Xue, Liu Yao, Zhu Bingbing, Niu Shuaishuai, Wang Xianbo

机构信息

Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University.

Department of infectious disease, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

出版信息

Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1352-1360. doi: 10.1097/MEG.0000000000001186.

DOI:10.1097/MEG.0000000000001186
PMID:29889683
Abstract

AIMS

The biochemical response after ursodeoxycholic acid (UDCA) treatment contributes toward predicting the prognosis for primary biliary cholangitis (PBC) patients. This study aimed to establish a score model that can be used for predicting the biochemical response.

PATIENTS AND METHODS

A total of 218 patients in the derivation group and 66 patients in the verification group were enrolled. Response endpoints were based on the Barcelona criteria combined with the Paris I criteria. We determined independent factors of the biochemical response by univariate and multivariate analyses. Then, we established a predictive score model on the basis of regression coefficients after adjusted multivariate analyses.

RESULTS

The median follow-up duration in the derivation and the verification group was 12.9 and 12.2 months, respectively. Multivariate logistic regression analysis after adjusting for sex and age indicated that First-UDCA treatment [odds ratio (OR)=2.543, 95% confidence interval (CI): 1.234-5.240, P=0.011], baseline alanine aminotransferase level (OR=1.265, 95% CI: 1.089-1.471, P=0.002), and baseline total bilirubin level (OR=0.571, 95% CI: 0.420-0.776, P<0.001) were independent factors that influenced the biochemical response in PBC patients after 1 year of UDCA treatment. Therefore, the resulting biochemical response prediction score model represented the sum of the points corresponding to these three variables. The area under the receiver operating characteristic curve of the score model in the derivation group and the verification group was 0.763 (95% CI: 0.701-0.817, P<0.001) and 0.798 (95% CI: 0.681-0.887, P<0.001), respectively.

CONCLUSION

We developed and verified an easy-to-use scoring model for the first time, which showed excellent predictive value for the biochemical response in PBC patients.

摘要

目的

熊去氧胆酸(UDCA)治疗后的生化反应有助于预测原发性胆汁性胆管炎(PBC)患者的预后。本研究旨在建立一个可用于预测生化反应的评分模型。

患者与方法

共纳入218例推导组患者和66例验证组患者。反应终点基于巴塞罗那标准并结合巴黎I标准。我们通过单因素和多因素分析确定生化反应的独立因素。然后,在调整后的多因素分析基础上,根据回归系数建立预测评分模型。

结果

推导组和验证组的中位随访时间分别为12.9个月和12.2个月。在对性别和年龄进行调整后的多因素逻辑回归分析表明,首次UDCA治疗[比值比(OR)=2.543,95%置信区间(CI):1.234 - 5.240,P = 0.011]、基线丙氨酸氨基转移酶水平(OR = 1.265,95% CI:1.089 - 1.471,P = 0.002)以及基线总胆红素水平(OR = 0.571,95% CI:0.420 - 0.776,P < 0.001)是影响UDCA治疗1年后PBC患者生化反应的独立因素。因此,所得的生化反应预测评分模型代表这三个变量对应的分数之和。该评分模型在推导组和验证组的受试者工作特征曲线下面积分别为0.763(95% CI:0.701 - 0.817,P < 0.001)和0.798(95% CI:0.681 - 0.887,P < 0.001)。

结论

我们首次开发并验证了一个易于使用的评分模型,该模型对PBC患者的生化反应具有出色的预测价值。

相似文献

1
Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment.原发性胆汁性胆管炎对熊去氧胆酸治疗生化反应的影响因素及预测评分模型
Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1352-1360. doi: 10.1097/MEG.0000000000001186.
2
Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.原发性胆汁性肝硬化患者接受熊去氧胆酸治疗结局预测评分系统的建立与验证。
Gastroenterology. 2015 Dec;149(7):1804-1812.e4. doi: 10.1053/j.gastro.2015.07.061. Epub 2015 Aug 7.
3
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.原发性胆汁性胆管炎患者对熊去氧胆酸应答的预处理预测:UDCA 应答评分的建立和验证。
Lancet Gastroenterol Hepatol. 2018 Sep;3(9):626-634. doi: 10.1016/S2468-1253(18)30163-8. Epub 2018 Jul 13.
4
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.原发性胆汁性肝硬化对熊去氧胆酸的生化反应及长期预后
Hepatology. 2008 Sep;48(3):871-7. doi: 10.1002/hep.22428.
5
Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.熊去氧胆酸治疗原发性胆汁性胆管炎患者的风险评分系统的验证。
Am J Gastroenterol. 2019 Jul;114(7):1101-1108. doi: 10.14309/ajg.0000000000000290.
6
Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.对熊去氧胆酸有生化反应的原发性胆汁性肝硬化患者预后改善。
Gastroenterology. 2009 Apr;136(4):1281-7. doi: 10.1053/j.gastro.2009.01.003. Epub 2009 Jan 14.
7
Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study.1 年时的生化指标并非原发性胆汁性胆管炎早期对熊去氧胆酸应答的可靠指标:来自一项 29 年队列研究的结果。
Aliment Pharmacol Ther. 2013 Dec;38(11-12):1354-64. doi: 10.1111/apt.12522. Epub 2013 Oct 5.
8
Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.原发性胆汁性胆管炎的长期非诺贝特治疗可改善生化指标,但不能改善英国原发性胆汁性胆管炎风险评分。
Dig Dis Sci. 2016 Oct;61(10):3037-3044. doi: 10.1007/s10620-016-4250-y. Epub 2016 Jul 19.
9
Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.原发性胆汁性胆管炎患者对熊去氧胆酸的生化反应:一项基于全国人口的研究。
Scand J Gastroenterol. 2019 May;54(5):609-616. doi: 10.1080/00365521.2019.1606931. Epub 2019 May 10.
10
Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.熊去氧胆酸对原发性胆汁性肝硬化患者肝脏生化指标的预后因素及长期影响。荷兰多中心原发性胆汁性肝硬化研究组。
J Hepatol. 1999 Aug;31(2):256-62. doi: 10.1016/s0168-8278(99)80222-0.

引用本文的文献

1
Risk Stratification in Primary Biliary Cholangitis.原发性胆汁性胆管炎的风险分层
J Clin Med. 2023 Sep 1;12(17):5713. doi: 10.3390/jcm12175713.
2
Prevalence and risk factors of osteoporosis detected by dual-energy X-ray absorptiometry among Chinese patients with primary biliary cholangitis.原发性胆汁性胆管炎患者双能 X 射线吸收法检测骨质疏松症的患病率和危险因素。
World J Gastroenterol. 2023 Aug 7;29(29):4580-4592. doi: 10.3748/wjg.v29.i29.4580.
3
Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice.性别与自身免疫性肝病:临床实践中的相关方面
J Pers Med. 2022 Jun 2;12(6):925. doi: 10.3390/jpm12060925.
4
External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis.UDCA 反应评分在斯洛伐克和克罗地亚原发性胆汁性胆管炎患者中的外部验证。
Can J Gastroenterol Hepatol. 2021 Jun 22;2021:9928065. doi: 10.1155/2021/9928065. eCollection 2021.
5
Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis.原发性胆汁性胆管炎中熊去氧胆酸治疗反应的预测模型
J Clin Transl Hepatol. 2021 Apr 28;9(2):187-193. doi: 10.14218/JCTH.2020.00127. Epub 2021 Mar 4.